A phase I trial of subcutaneous sevuparin for the treatment of sickle cell disease.
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2018
At a glance
- Drugs Sevuparin (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 25 Nov 2018 New trial record
- 07 Nov 2018 According to a Modus Therapeutics media release, the company announces that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate this trial.